| Name | (4S)-N-[(2S)-1-Hydroxy-2-propanyl]-4-methyl-1-[2-methyl-4-(3-methyl-1H-pyrazol-1-yl)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine-4-carboxamide |
|---|---|
| Synonyms |
1H-1-Benzazepine-4-carboxamide, 2,3,4,5-tetrahydro-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl-1-[2-methyl-4-(3-methyl-1H-pyrazol-1-yl)benzoyl]-, (4S)-
(4S)-N-[(2S)-1-Hydroxy-2-propanyl]-4-methyl-1-[2-methyl-4-(3-methyl-1H-pyrazol-1-yl)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine-4-carboxamide |
| Description | Lazuvapagon is a vasopressin V2 receptor agonist for the research of nocturia[1]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 712.1±60.0 °C at 760 mmHg |
| Molecular Formula | C27H32N4O3 |
| Molecular Weight | 460.57 |
| Flash Point | 384.5±32.9 °C |
| Exact Mass | 460.247437 |
| LogP | 2.79 |
| Vapour Pressure | 0.0±2.4 mmHg at 25°C |
| Index of Refraction | 1.623 |